The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1558
October 22, 2018
View Complete Issue         Table of Contents 2019 
OTC Brimonidine (Lumify) for Ocular Redness
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
OTC Brimonidine (Lumify) for Ocular Redness
October 22, 2018 (Issue: 1558)
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: OTC Brimonidine (Lumify) for Ocular Redness
Article code: 1558c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.